Showing results (1-10 of 76) with videos related to
Sort By:
Pageof 8
Clinical Immunology (Orlando, Fla.)|November 12, 2018
Natural and modified IL-2 for the treatment of cancer and autoimmune diseasesMasayuki MizuiClinical Immunology (Orlando, Fla.)|March 8, 2024
Novel therapeutic strategies targeting abnormal T-cell signaling in systemic lupus erythematosusMasayuki Mizui, Michihito KonoNihon Rinsho Men'Eki Gakkai Kaishi = Japanese Journal of Clinical Immunology|July 6, 2005
[Involvement of semaphorins in immunoregulation]Masayuki Mizui, Atsushi KumanogohImmunity|March 18, 2008
Neuropilin-1: the glue between regulatory T cells and dendritic cells?Masayuki Mizui, Hitoshi KikutaniCurrent Rheumatology Reports|October 14, 2016
Low-Dose IL-2 in the Treatment of LupusMasayuki Mizui, George C TsokosFrontiers in Immunology|May 15, 2018
Targeting Regulatory T Cells to Treat Patients With Systemic Lupus ErythematosusMasayuki Mizui, George C TsokosJournal of Clinical Immunology|December 11, 2008
Immune semaphorins: novel features of neural guidance moleculesMasayuki Mizui, Atsushi Kumanogoh, Hitoshi KikutaniClinical Immunology (Orlando, Fla.)|April 15, 2015
Signal transducer and activator of transcription (STAT) 3 inhibition delays the onset of lupus nephritis in MRL/lpr miceLindsay J Edwards, Masayuki Mizui, Vasileios KyttarisKidney International|April 17, 2004
Gene therapy in renal diseasesEnyu Imai, Yoshitsugu Takabatake, Masayuki Mizui, et al.Molecular Neurobiology|June 19, 2017
Semaphorin4D-PlexinB1 Signaling Attenuates Photoreceptor Outer Segment Phagocytosis by Reducing Rac1 Activity of RPE CellsAyelen Bulloj, Arvydas Maminishkis, Masayuki Mizui, et al.Pageof 8